Two randomized controlled trials of SB742457 in mild-to-moderate Alzheimer's disease

BACKGROUND: Two previous studies of SB742457, a 5-hydroxytryptamine (5-HT(6)) receptor antagonist, suggested the efficacy of improvements in cognition and global outcome in Alzheimer's disease (AD). METHODS: Two randomized, placebo-controlled trials investigated SB742457 15 and 35 mg daily in s...

Descripción completa

Detalles Bibliográficos
Autores principales: Maher-Edwards, Gareth, Watson, Carolyn, Ascher, John, Barnett, Carly, Boswell, Diane, Davies, John, Fernandez, Manuel, Kurz, Alexander, Zanetti, Orazio, Safirstein, Beth, Schronen, Juan Paul, Zvartau-Hind, Marina, Gold, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2015
Materias:
Featured Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5974972/
https://www.ncbi.nlm.nih.gov/pubmed/29854923
http://dx.doi.org/10.1016/j.trci.2015.04.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5974972/
https://www.ncbi.nlm.nih.gov/pubmed/29854923
http://dx.doi.org/10.1016/j.trci.2015.04.001

Ejemplares similares